HRMY

32.03

1.36% 0.43

Dopo l'orario di chiusura: 32.03

Harmony Biosciences Holdings Inc (HRMY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HRMY Giù? Forum Previsione

Precedente Chiudi:

$31.60

Aprire:

$32

Volume 24 ore:

829.35K

Relative Volume:

1.20

Capitalizzazione di mercato:

$2.06B

Reddito:

$681.88M

Utile/perdita netta:

$122.63M

Rapporto P/E:

15.18

EPS:

2.11

Flusso di cassa netto:

$220.18M

1 W Prestazione:

-0.09%

1M Prestazione:

-7.16%

6M Prestazione:

-6.92%

1 anno Prestazione:

+5.29%

Intervallo 1D:

$31.82

$33.69

Intervallo di 1 settimana:

$31.25

$33.69

Portata 52W:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Nome

Harmony Biosciences Holdings Inc

Settore

Healthcare (1166)

Industria

Biotechnology (655)

Telefono

(484) 539-9800

Indirizzo

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Dipendente

268

Cinguettio

Prossima data di guadagno

2024-10-29

Ultimi documenti SEC

HRMY's Discussions on Twitter

Confronta HRMY con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HRMY Harmony Biosciences Holdings Inc	32.03	2.06B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	452.16	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	534.91	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	322.06	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	542.47	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.16	28.51B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-02	Ripresa	Oppenheimer	Outperform
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-12-17	Iniziato	H.C. Wainwright	Buy
2024-10-10	Ripresa	Raymond James	Outperform
2024-09-10	Iniziato	UBS	Buy
2024-06-21	Iniziato	Citigroup	Buy
2024-01-02	Downgrade	BofA Securities	Neutral → Underperform
2023-09-25	Downgrade	Goldman	Neutral → Sell
2023-09-07	Iniziato	Berenberg	Buy
2023-04-20	Iniziato	BofA Securities	Neutral
2022-10-14	Aggiornamento	Janney	Neutral → Buy
2022-10-14	Aggiornamento	Jefferies	Hold → Buy
2022-08-03	Downgrade	Jefferies	Buy → Hold
2022-07-13	Downgrade	Goldman	Buy → Neutral
2022-07-07	Iniziato	Mizuho	Buy
2022-04-14	Iniziato	Cantor Fitzgerald	Overweight
2021-12-01	Iniziato	Oppenheimer	Outperform
2021-11-04	Iniziato	Raymond James	Outperform
2021-09-23	Iniziato	Needham	Buy
2021-03-29	Aggiornamento	Goldman	Neutral → Buy
2020-09-14	Iniziato	Goldman	Neutral
2020-09-14	Iniziato	Jefferies	Buy
2020-09-14	Iniziato	Piper Sandler	Overweight

Mostra tutto

Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie

Jun 16, 2025

Lupin Concedes To Harmony On Generic Wakix With 2030 Launch Agreement - insights.citeline.com

Jun 16, 2025

Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment - MyChesCo

Jun 16, 2025

Jun 15, 2025

Rhumbline Advisers Increases Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Jun 15, 2025

Jun 14, 2025

Harmony Biosciences to begin human trials of narcolepsy drug in 2025 By Investing.com - Investing.com South Africa

Jun 11, 2025

Harmony Biosciences to begin human trials of narcolepsy drug in 2025 - Investing.com Canada

Jun 11, 2025

HRMY: Harmony Biosciences Shows Promising Preclinical Data for BP1.15205 | HRMY Stock News - GuruFocus

Jun 11, 2025

Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 - StreetInsider

Jun 11, 2025

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 - Business Wire

Jun 11, 2025